Drug Profile


Alternative Names: CSG-EGFR; Epidermal growth factor chimeric-antigen receptor-T-cell-therapy

Latest Information Update: 28 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CARsgen
  • Class CAR-T cell therapies
  • Mechanism of Action Epidermal growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioblastoma
  • Preclinical Cancer

Most Recent Events

  • 23 Oct 2015 Preclinical trials in Cancer in China (Parenteral) prior to October 2015
  • 01 Dec 2014 Phase-I clinical trials in Glioblastoma (In adults, In the elderly, Second-line therapy or greater, Recurrent) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top